EUVIMEDScopri EUVIMED
Crossref

Isoliquiritin treatment of osteoporosis by promoting osteogenic differentiation and autophagy of bone marrow mesenchymal stem cells

Zhikang Su, Ding Chen, Jiangyon Huang, Zitian Liang, Wen Ren, Zeyu Zhang, Qianzhou Jiang, Tao Luo, Lvhua Guo iD

Phytotherapy Research · 2024

DOI: 10.1002/ptr.8032 ↗

At a glance

Journal article in Phytotherapy Research, 2024. Written by Zhikang Su and 8 co-authors. Institution: Department of Prosthodontics, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction & Guan…. Major MEDLINE topics: Osteoporosis, Mesenchymal Stem Cells, Glucosides. Cited 13 times so far (Crossref); 47 references. Funded by: Guangdong Provincial Science and Technology Plan Project, Key Projects of Science and Technology Plan of Liwan District of Guangzhou City, Research and Development Plan of Key Areas of Scientific Research Institutions in Guangdong Province.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Osteoporosis is a chronic progressive bone disease characterized by the decreased osteogenic ability of osteoblasts coupled with increased osteoclast activity. Natural products showing promising therapeutic potential for postmenopausal osteoporosis remain underexplored. In this study, we aimed to analyze the therapeutic effects of isoliquiritin (ISL) on osteoporosis in mice and its possible mechanism of action. An ovariectomy‐induced osteoporosis mouse model and bone marrow mesenchymal stem cells (BMSCs) were used to analyze the effects of ISL on bone regeneration in vivo and in vitro, respectively. Mitogen‐activated protein kinase (MAPK) and autophagy inhibitors were used, to investigate whether the MAPK signaling pathway and autophagy affect the osteogenic differentiation of BMSCs. ISL significantly improved bone formation and reduced bone resorption in mouse femurs without inducing any detectable toxicity in critical organs such as the liver, kidney, brain, heart, and spleen. In vitro experiments showed that ISL enhanced the proliferation and osteogenic differentiation of BMSCs and that its osteogenic effect was attenuated by p38/extracellular regulated protein kinase (ERK) and autophagy inhibitors. Further studies showed that the inhibition of phosphorylated p38/ERK blocked ISL autophagy in BMSCs. ISL promoted the osteogenic differentiation of BMSCs through the p38/ERK‐autophagy pathway and was therapeutically effective in treating osteoporosis in ovariectomized mice without any observed toxicity to vital organs. These results strongly suggest the promising potential of ISL as a safe and efficacious candidate drug for the treatment of osteoporosis.

Subjects

MeSH terms (MEDLINE)

OsteoporosisMesenchymal Stem CellsGlucosidesFemaleMiceAnimalsOsteogenesisCells, CulturedCell DifferentiationAutophagyBone Marrow CellsChalcone

Author keywords

MAPKautophagybone marrow mesenchymal stem cellsisoliquiritinosteoporosis

Substances

neoisoliquiritinChalconeGlucosides

Authors and institutions

  • Department of Prosthodontics, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction & Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerativ…
  • Department of Dentistry and Endodontics, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction & Guangzhou Key Laboratory of Basic and Applied Research of Oral…

ORCID profiles: Lvhua Guo

Funding

  • Guangdong Provincial Science and Technology Plan Project
  • Key Projects of Science and Technology Plan of Liwan District of Guangzhou City
  • Research and Development Plan of Key Areas of Scientific Research Institutions in Guangdong Province
  • Key Technology Research and Development of Oral High-Performance Implantable Medical Devices

Cite

APA

Su, Z., Chen, D., Huang, J., Liang, Z., Ren, W., Zhang, Z., Jiang, Q., Luo, T., & Guo, L. (2024). Isoliquiritin treatment of osteoporosis by promoting osteogenic differentiation and autophagy of bone marrow mesenchymal stem cells. Phytotherapy Research. https://doi.org/10.1002/ptr.8032

Vancouver

Su Z, Chen D, Huang J, Liang Z, Ren W, Zhang Z, et al. Isoliquiritin treatment of osteoporosis by promoting osteogenic differentiation and autophagy of bone marrow mesenchymal stem cells. Phytotherapy Research. 2024. doi:10.1002/ptr.8032

BibTeX
@article{Su2024,
  author = {Su, Zhikang and Chen, Ding and Huang, Jiangyon and Liang, Zitian and Ren, Wen and Zhang, Zeyu and Jiang, Qianzhou and Luo, Tao and Guo, Lvhua},
  title = {Isoliquiritin treatment of osteoporosis by promoting osteogenic differentiation and autophagy of bone marrow mesenchymal stem cells},
  journal = {Phytotherapy Research},
  year = {2024},
  doi = {10.1002/ptr.8032}
}
Start for free →